Today: 8 July 2026
Browse Category

NASDAQ:LNAI 5 November 2025 - 17 June 2026

Lunai Bioworks stock jumps after Nasdaq bid-price compliance filing

Lunai Bioworks stock jumps after Nasdaq bid-price compliance filing

Lunai Bioworks Inc. shares surged in early U.S. trading on Wednesday after a company filing showed Nasdaq had confirmed the biotechnology firm was back in compliance with the exchange’s $1 minimum bid-price rule, a key threshold for keeping a listing on the market. The stock was quoted at $4.65, with reported volume of 13.48 million shares, compared with average volume of 1.98 million. The move matters because Lunai had been fighting to stay on Nasdaq. The minimum bid price is the exchange rule that generally requires listed shares to trade at or above $1; falling below it can lead to delisting, which often hurts liquidity and access to investors. Nasdaq told the company on June 11 that it had regained compliance, according to the Form 8-K signed by Chief Executive David Weinstein and filed June 16.
17 June 2026
··
From Crash to Breakthrough: Why Lunai Bioworks (LNAI) Is Suddenly on Investors’ Radar

From Crash to Breakthrough: Why Lunai Bioworks (LNAI) Is Suddenly on Investors’ Radar

Lunai Bioworks Inc. is a pre-clinical stage biotechnology company pioneering an unusual dual focus: AI-driven drug discovery and biodefense. The company’s mission is to “capture biological signals at scale, decode them with AI, and rapidly validate insights in model systems”, bridging cutting-edge computation with experimental biotechainvest.comainvest.com. In practical terms, Lunai is developing both therapeutic platforms and advanced diagnostics/screening tools, all underpinned by machine learning. Core Technology & Pipeline: Lunai’s flagship approach is a next-generation allogeneic dendritic cell therapy for cancer. Dendritic cells are immune “sentinel” cells; Lunai engineers them from stem cells and genetically enhances them to train the immune system to attack tumorsprnewswire.comprnewswire.com. Its lead constructs, formerly labeled RENB-DC11 and RENB-DC20, showed potent anti-tumor activity in preclinical studiesstockanalysis.comprnewswire.com. The latest Vaccines publication on Nov 2, 2025 demonstrated a “clinical-grade” second-generation DC therapy achieving complete regression of pancreatic tumors in humanized miceprnewswire.comprnewswire.com. This suggests Lunai’s immunotherapy platform is nearing IND-enabling studies, a point CEO David Weinstein emphasizes as bringing the platform “to the threshold of clinical translation”prnewswire.com.
5 November 2025
···

Stock Market Today

  • Fortis, Canadian National Railway seen as defensive TSX picks in slower economy
    July 7, 2026, 10:07 PM EDT. Investors are turning to steady stocks like Fortis (TSX:FTS) and Canadian National Railway (TSX:CNR) as GDP growth stalls and interest rates hold in 2026. Fortis, a North American utility, brings regulated electricity and gas cash flow, is running a $28.8 billion capital plan, and yields 3.1% after 52 straight years of raising its dividend. Canadian National Railway runs its rail network from coast to coast, moving all kinds of goods and supporting trade. Both names are pitched as resilient TSX plays with some growth potential as markets stay choppy.
Go toTop